Approximately 30% of patients with advanced, metastatic differentiated thyroid cancer have
radioiodine-refractory disease, based on decreased expression of the sodium iodide …

The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …

Radioactive iodine (RAI) is a key therapeutic modality for thyroid cancer. Loss of RAI uptake
in thyroid cancer inversely correlates with patient's survival. In this review, we focus on the …

The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …

Simple Summary This year marks the 80th commemoration of the first time that radio-iodide
treatment (RAI) was used. RAI is one of the most effective targeted internal radiation …

The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated
thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine …

Background Expression and function of sodium iodide symporter (NIS) is requisite for
efficient iodide transport in thyrocytes, and its presence in cancer cells allows the use of …

Active iodide (I−) transport in both the thyroid and some extrathyroidal tissues is mediated by
the Na+/I− symporter (NIS). In the thyroid, NIS-mediated I− uptake plays a pivotal role in …

Radioiodine-concentrating activity in thyroid tissues has allowed the use of radioiodine as a
diagnostic and therapeutic agent for patients with thyroid disorders such as well …